We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Summit Therapeutics Plc | LSE:SUMM | London | Ordinary Share | GB00BN40HZ01 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 20.50 | 18.00 | 23.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMSUMM Summit Therapeutics plc ("Summit Therapeutics" or the "Company") Award of Restricted Stock Units Oxford, UK, and Cambridge, MA, US, 14 January 2019 - Summit Therapeutics (AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovation, announces a grant of restricted stock units ('RSUs') was made to the Non-Executive Directors on 11 January 2019. This grant is made according to the Company's 2017 Remuneration Policy and represents the annual grant of RSUs to the Company's Non-Executive Directors for the calendar year 2019. Details of the RSU grant are summarised below. The Company also announces that its Non-Executive Chairman, Dr Frank Armstrong, has surrendered 37,500 share options. The surrendered share options were awarded in July 2014 and vested in March 2017. The decision to surrender is part of the Company's objective of meeting best UK corporate governance practice that favours non-performance remuneration such as RSUs. As a result of this surrender, none of the Non-Executive Directors now hold any share options, with any outstanding awards having been surrendered during the current financial year. Details of the Award of Restricted Stock Units Director Position RSU's Awarded Total RSUs Held -------------------- ----------------------- ------------- --------------- Frank Armstrong Non-Executive Chairman 288,461 325,046 -------------------- ----------------------- ------------- --------------- Leopoldo Zambeletti Non-Executive Director 134,615 151,688 -------------------- ----------------------- ------------- --------------- Valerie Andrews Non-Executive Director 134,615 151,688 -------------------- ----------------------- ------------- --------------- Dave Wurzer Non-Executive Director 134,615 151,688 -------------------- ----------------------- ------------- --------------- Each RSU entitles the holder to subscribe for an Ordinary Share at a subscription price of one penny per Ordinary Share. The RSUs have a vesting period of one year and no performance conditions. The RSUs granted will vest on 11 January 2020. This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (MAR). About Summit Therapeutics Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for infections caused by C. difficile, N. Gonorrhoeae and ESKAPE pathogens and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc. For more information, please contact: Summit Glyn Edwards / Richard Pye (UK office) Tel: +44 (/0)1235 443 951 Michelle Avery (US office) +1 617 225 4455 Cairn Financial Advisers LLP (Nominated Adviser) Tel: +44 (0)20 7213 0880 Liam Murray / Tony Rawlinson N+1 Singer (Joint Broker) Tel: +44 (0)20 7496 3000 Aubrey Powell / Jen Boorer, Corporate Finance Tom Salvesen, Corporate Broking Bryan Garnier & Co Limited (Joint Broker) Tel: +44 (0)20 7332 2500 Phil Walker / Dominic Wilson MSL Group (US) Tel: +1 781 684 6557 mailto:summit@mslgroup.com Jon Siegal summit@mslgroup.com ------------------------------ Consilium Strategic Communications (UK) Tel: +44 (0)20 3709 5700 Mary-Jane Elliott / Sue Stuart / Jessica Hodgson / mailto:summit@consilium-comms. com summit@consilium-comms.com ------------------------------ Lindsey Neville Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 Details of the person discharging managerial responsibilities/person 1 closely associated --- ----------------------------------------------------------------------------- a) Name Dr Frank Armstrong --- ----------------------------- ---------------------------------------------- 2 Reason for the notification --- ----------------------------------------------------------------------------- a) Position / status Non-Executive Chairman --- ----------------------------- ---------------------------------------------- Initial notification / b) Amendment Initial notification --- ----------------------------- ---------------------------------------------- Details of the issuer, emission allowance market participant, 3 auction platform, auctioneer or auction monitor --- ----------------------------------------------------------------------------- a) Name Summit Therapeutics plc --- ----------------------------- ---------------------------------------------- b) LEI 213800NRW8AOMYMTBD89 --- ----------------------------- ---------------------------------------------- Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place 4 where transactions have been conducted --- ----------------------------------------------------------------------------- Description of the financial instrument, type of instrument Ordinary shares of 1 penny each --- a) Identification code GB00BN40HZ01 --- ----------------------------- ---------------------------------------------- b) Nature of the transactions Grant of restricted stock units --- ----------------------------- ---------------------------------------------- Price(s) Volume(s) --- ----------------------------- ------------------------------ ----------- 1 penny per share (subscription price) 288,461 ---------------------------------------------------------------- ----------- c) Price(s) and volume(s) --- -------------------------------------------------------------- ------------- Aggregated information - Aggregated volume N/A d) - Price --- -------------------------------------------------------------- ------------- e) Date of the transaction 11 January 2019 --- ----------------------------- ---------------------------------------------- f) Place of the transaction Outside a trading venue --- ----------------------------- ---------------------------------------------- Details of the person discharging managerial responsibilities/person 1 closely associated --- ----------------------------------------------------------------------------- a) Name Leopoldo Zambeletti --- ----------------------------- ---------------------------------------------- 2 Reason for the notification --- ----------------------------------------------------------------------------- a) Position / status Non-Executive Director --- ----------------------------- ---------------------------------------------- Initial notification / b) Amendment Initial notification --- ----------------------------- ---------------------------------------------- Details of the issuer, emission allowance market participant, 3 auction platform, auctioneer or auction monitor --- ----------------------------------------------------------------------------- a) Name Summit Therapeutics plc --- ----------------------------- ---------------------------------------------- b) LEI 213800NRW8AOMYMTBD89 --- ----------------------------- ---------------------------------------------- Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place 4 where transactions have been conducted --- ----------------------------------------------------------------------------- Description of the financial instrument, type of instrument Ordinary shares of 1 penny each --- a) Identification code GB00BN40HZ01 --- ----------------------------- ---------------------------------------------- b) Nature of the transactions Grant of restricted stock units --- ----------------------------- ---------------------------------------------- Price(s) Volume(s) --- ----------------------------- ------------------------------ ----------- 1 penny per share (subscription price) 134,615 ---------------------------------------------------------------- ----------- c) Price(s) and volume(s) --- -------------------------------------------------------------- ------------- Aggregated information - Aggregated volume N/A d) - Price --- -------------------------------------------------------------- ------------- e) Date of the transaction 11 January 2019 --- ----------------------------- ---------------------------------------------- f) Place of the transaction Outside a trading venue
--- ----------------------------- ---------------------------------------------- Details of the person discharging managerial responsibilities/person 1 closely associated --- ----------------------------------------------------------------------------- a) Name Valerie Andrews --- ----------------------------- ---------------------------------------------- 2 Reason for the notification --- ----------------------------------------------------------------------------- a) Position / status Non-Executive Director --- ----------------------------- ---------------------------------------------- Initial notification / b) Amendment Initial notification --- ----------------------------- ---------------------------------------------- Details of the issuer, emission allowance market participant, 3 auction platform, auctioneer or auction monitor --- ----------------------------------------------------------------------------- a) Name Summit Therapeutics plc --- ----------------------------- ---------------------------------------------- b) LEI 213800NRW8AOMYMTBD89 --- ----------------------------- ---------------------------------------------- Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place 4 where transactions have been conducted --- ----------------------------------------------------------------------------- Description of the financial instrument, type of instrument Ordinary shares of 1 penny each --- a) Identification code GB00BN40HZ01 --- ----------------------------- ---------------------------------------------- b) Nature of the transactions Grant of restricted stock units --- ----------------------------- ---------------------------------------------- Price(s) Volume(s) --- ----------------------------- ------------------------------ ----------- 1 penny per share (subscription price) 134,615 ---------------------------------------------------------------- ----------- c) Price(s) and volume(s) --- -------------------------------------------------------------- ------------- Aggregated information - Aggregated volume N/A d) - Price --- -------------------------------------------------------------- ------------- e) Date of the transaction 11 January 2019 --- ----------------------------- ---------------------------------------------- f) Place of the transaction Outside a trading venue --- ----------------------------- ---------------------------------------------- Details of the person discharging managerial responsibilities/person 1 closely associated --- ----------------------------------------------------------------------------- a) Name Dave Wurzer --- ----------------------------- ---------------------------------------------- 2 Reason for the notification --- ----------------------------------------------------------------------------- a) Position / status Non-Executive Director --- ----------------------------- ---------------------------------------------- Initial notification / b) Amendment Initial notification --- ----------------------------- ---------------------------------------------- Details of the issuer, emission allowance market participant, 3 auction platform, auctioneer or auction monitor --- ----------------------------------------------------------------------------- a) Name Summit Therapeutics plc --- ----------------------------- ---------------------------------------------- b) LEI 213800NRW8AOMYMTBD89 --- ----------------------------- ---------------------------------------------- Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place 4 where transactions have been conducted --- ----------------------------------------------------------------------------- Description of the financial instrument, type of instrument Ordinary shares of 1 penny each --- a) Identification code GB00BN40HZ01 --- ----------------------------- ---------------------------------------------- b) Nature of the transactions Grant of restricted stock units --- ----------------------------- ---------------------------------------------- Price(s) Volume(s) --- ----------------------------- ------------------------------ ----------- 1 penny per share (subscription price) 134,615 ---------------------------------------------------------------- ----------- c) Price(s) and volume(s) --- -------------------------------------------------------------- ------------- Aggregated information - Aggregated volume N/A d) - Price --- -------------------------------------------------------------- ------------- e) Date of the transaction 11 January 2019 --- ----------------------------- ---------------------------------------------- f) Place of the transaction Outside a trading venue --- ----------------------------- ---------------------------------------------- -END-
(END) Dow Jones Newswires
January 14, 2019 07:00 ET (12:00 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Summit Therapeutics Chart |
1 Month Summit Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions